查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197905

患者自控镇痛泵市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Patient-Controlled Analgesia Pumps Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，患者自控镇痛 (PCA) 泵市场的复合年增长率预计为 5.2%。

COVID-19 大流行给医疗保健系统带来了巨大挑战。 在 COVID-19 的初始阶段，由于几个不确定的原因，患者自控镇痛泵市场的扩张受到显着限制。 然而，从 COVID-19 感染中康復的患者慢性疼痛的发生率正在增加。 例如，根据 2022 年 3 月的当前疼痛和头痛报告，在美国接种 COVID-19 疫苗可能减少了新的 SARS-CoV-2 感染，但长期接触该病毒的人数增加了。患有常见症状的人越来越多。 其长期副作用之一是慢性疼痛综合症。 因此，为了控制 COVID-19 康復患者的慢性疼痛，需要患者自控镇痛泵来帮助患者控制疼痛。 预计这将在预测期内对市场产生积极影响。

市场增长的主要推动因素是关节炎、癌症和纤维肌痛等慢性疼痛疾病的患病率上升，以及与 PCA 泵安全特性增强相关的技术进步。 纤维肌痛是一种引起全身疼痛的疾病，也称为瀰漫性疼痛。 纤维肌痛症患病率的增加将有助于患者自控镇痛泵市场的增长。 例如，根据 CDC 2022 年 5 月的更新，大约有 400 万美国公民（占所有成年人的 2%）患有纤维肌痛。 虽然纤维肌痛的病因尚不清楚，但可以通过多种疼痛管理方式对其进行治疗和管理，其中之一就是患者自控镇痛泵。 因此，纤维肌痛等慢性疼痛疾病的巨大负担将增加患者自控镇痛泵的使用，推动研究期间的市场增长。

监管机构最近的产品发布和批准主要集中在患者自控镇痛泵上，预计将有助于市场增长，因为这些批准增加了产品的可用性和市场竞争。 例如，2021 年 4 月，Becton Dickinson & Company 向美国 FDA 提交了 BD Alaris 系统的 510(k) 上市前通知。 该系统使临床医生能够通过一个集成平台提供止痛药和液体，该平台包括用于成人、儿科和新生儿患者的大容量泵和注射泵。 因此，预计在预测期内，受慢性疼痛疾病影响的大量人口和产品批准的增加将刺激研究市场的增长。 然而，缺乏意识、严格的监管框架以及导致患者用药错误的相关产品召回可能会减缓预测期内的市场增长。

PCA 市场趋势

肿瘤学有望在预测期内占据主要市场份额

由于癌症在全球范围内广泛流行，预计在预测期内，癌症细分市场将占据很大的市场份额。 癌症疼痛通常被描述为抽动、压迫、灼痛或刺痛感，可以使用 PCA 泵来控制。 因此，随着癌症负担的增加，预计对 PCA 泵的需求也会增加。 例如，根据 2021 年加拿大癌症统计数据，加拿大将在 2021 年发现 229,200 例新癌症病例。 同样，CMAJ Group 在 2022 年发布的一份报告估计，2022 年加拿大将有 233,900 人被诊断出患有癌症。 因此，该地区新癌症病例的增加将增加对疼痛管理的需求，而疼痛管理可以使用患者控制的止痛泵来实现。 因此，市场增长是可预期的。 医生会通过患者自控镇痛 (PCA) 输注高活性阿片类药物，例如氢吗啡、吗啡和芬太□□尼，以治疗难以忍受的疼痛。 在这种情况下，越来越多地采用 PCA 泵来提高生活质量有望推动这一领域的增长。

同样，通过使用患者自控镇痛药来提高患者对癌症疼痛管理的满意度也将在市场增长中发挥重要作用。 例如，根据 2021 年 8 月发表在 JNCCN 期刊上的一篇论文，可编程患者自控镇痛 (PCA) 泵可以帮助患者按需控制疼痛并快速响应不断变化的患者需求，并且可以减少镇痛药物的延迟。 PCA 显着降低了持续性严重癌症疼痛的滴定成功率和平均疼痛评分。 因此，对 PCA 泵用于癌症疼痛管理的偏好预计将推动该细分市场的增长。

预计在预测期内北美将占据很大的市场份额

由于癌症、意外伤害和其他疼痛相关疾病的病例不断增加，以及慢性疼痛的研究支出不断增加，预计北美将主导整个 PCA 泵市场。

由于癌症患者比例高，预计北美地区将刺激市场增长。 例如，根据 ACS 2021 & 2022 报告，2021 年美国估计将有 1,898,160 例新癌症病例，到 2022 年将上升到 1,918,030 例。 排除黑色素瘤以外的皮肤癌，美国 42% 的新诊断癌症病例，即 2022 年的约 805,600 例，是可以预防的。 因此，预计该地区癌症患者患病率上升将在预测期内推动该地区的市场增长。

此外，慢性疼痛研究经费的增加预计也将推动该地区的市场增长。 例如，根据 NIH 2022，美国在 2021 年、2022 年和 2023 年用于慢性疼痛的研究经费预计分别为 7.25 亿美元、7.5 亿美元和 8.62 亿美元。 该地区主要市场参与者之间的联盟和收购也在推动市场增长。 例如，2022 年 1 月，总部位于加利福尼亚州的 ICU Medical 从 Smiths Group Plc 收购了 Smiths Medical Division，该部门包括注射器、门诊输液设备、血管通路和重要护理产品。 此类活动可能会扩大公司的投资组合，并有望在北美地区的预测期内实现显着增长。

PCA（患者自控镇痛）泵市场竞争对手分析

PCA（患者自控镇痛）泵市场竞争适中，由几家大型企业组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 一些着名的参与者使用新技术开发了安全无故障的系统，其他人也出售这些系统。 目前主导市场的公司包括 ICU Medical Inc. (Smiths Medical)、BD (Becton, Dickinson and Company)、Fresenius SE & Co. KGaA、B. Braun SE 和 Baxter。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 提高安全性的技术进步
    • 癌症和关节炎等慢性疼痛疾病的增加
  • 市场製约因素
    • 意识不足导致患者误认药物
    • 严格的监管框架和产品召回
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按产品类型
    • PCA 泵
    • 泵配件
  • 通过申请
    • 肿瘤学
    • 糖尿病
    • 新生儿科
    • 其他用途
  • 最终用户
    • 医院
    • 门诊手术中心
    • 家庭护理
  • 区域信息
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • ICU Medical Inc.（Smiths Medical）
    • Baxter
    • BD（Becton, Dickinson and Company）
    • Fresenius SE & Co. KGaA
    • Micrel Medical Devices
    • Avante Health Solutions
    • B. Braun SE
    • Ace Medical
    • Terumo Corporation
    • Abbott
    • Pfizer Inc.（Hospira）

第7章 市场机会今后动向

简介目录
Product Code: 68518

The patient-controlled analgesia (PCA) pump market is expected to register a CAGR of 5.2% over the forecast period.

The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. During the first phase of COVID-19, the expansion of the patient-controlled analgesia pump market was significantly constrained for several uncertain reasons. However, there is an increasing occurrence of chronic pain in patients who recovered from COVID-19 infection. For instance, as per the Current Pain and Headache Reports in March 2022, the vaccination for COVID-19 in the United States may be reducing the number of new SARS-CoV-2 cases, but the population of those suffering from the virus's long-term symptoms is growing. One of these long-term side effects includes chronic pain syndromes. Hence, to manage the chronic pain of COVID-19-recovered patients, there is a need for patient-controlled analgesia pumps, which help the patient control their pain. This is expected to positively impact the market over the forecast period.

The major factors attributing to the market's growth are the increasing prevalence of chronic pain diseases such as arthritis, cancer, and fibromyalgia, along with the technological advancements with enhanced safety features in the PCA pumps. Fibromyalgia is a condition that causes pain all over the body, also called widespread pain. The increase in the prevalence of fibromyalgia helps the growth of the patient-controlled analgesia pump market. For instance, according to the updated data from CDC in May 2022, about 4 million US citizens, or 2% of all adults, suffer from fibromyalgia. Although there is no known cause for fibromyalgia, it is treatable and manageable with various pain management methods, one of which is a patient-controlled analgesia pump. Hence a significant burden of chronic pain diseases like fibromyalgia increases the usage of patient-controlled analgesia pumps and drives the market's growth over the study period.

The recent product launches and approvals by the regulatory authorities focusing on patient-controlled analgesia pumps are expected to aid in the market's growth, as these approvals will increase product availability and competition in the market. For instance, in April 2021, Becton, Dickinson, and Company submitted a 510(k) premarket notification to the US FDA for the BD Alaris System. The system allows clinicians to deliver pain medications and fluids through a single integrated platform that includes large-volume pumps and syringe pumps for adult, pediatric and neonatal patients. Thus, the large population affected by chronic pain-causing diseases and the increasing product approvals are expected to add to the growth of the studied market over the forecast period. However, the lack of awareness resulting in patient medication errors and the stringent regulatory framework and associated product recalls are likely to slow down the market growth over the forecast period.

Patient-controlled Analgesia Pumps Market Trends

Oncology is Expected to Hold the Major Market Share in the Market Over the Forecast Period

The oncology segment is expected to account for a significant market share during the forecast period due to the widespread prevalence of cancers worldwide. Cancer pain is often described as a throbbing, pressing, burning, or tingling sensation that can be managed through PCA pumps, and hence, the demand for PCA pumps is expected to increase with the rising burden of cancer. For Instance, according to the Canadian Cancer Statistics 2021, in Canada, 229,200 new cancer cases were detected in 2021. Similarly, as per the report published by the CMAJ Group in 2022, an estimated 233,900 people in Canada will be diagnosed with cancer in 2022. ​Thus, the increase in new cases of cancer in the region will increase the demand for pain management, which can be achieved using patient-controlled analgesia pumps. Therefore, growth in the market is expected. Highly potent opioid drugs, such as hydro morphine, morphine, and fentanyl through patient-controlled analgesia (PCA) infusion, are prescribed by physicians to treat unbearable pain. The rising adoption of PCA pumps in such conditions to improve the quality of life is expected to promote the segment's growth.

Similarly, the increase in patient satisfaction with cancer pain management with the use of patient-controlled analgesics plays a significant role in market growth. For instance, as per an article published by the JNCCN Journal in August 2021, the programmable patient-controlled analgesia (PCA) pump allows patients to control pain on demand and also promptly responds to the patient's changing needs, and it reduces analgesic delay. The PCA significantly reduced successful titration and average pain score for persistent severe cancer pain. Thus, the preference for PCA pumps for cancer pain management is expected to boost the growth of the segment.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to dominate the overall PCA pumps market owing to the rise in the number of cases of cancer, accidental injuries, and other ailments related to pain and the rise in research funding on chronic pain.

The high prevalence of cancer cases in the North American region is expected to add to the market's growth. For instance, as per the ACS 2021 & 2022 report, in the United States, 1,898,160 new cancer cases were estimated in 2021, which is going to rise in 2022 to 1,918,030 new cancer cases. Excluding non-melanoma skin cancer, 42% of cancer cases in the United States that are newly diagnosed, or around 805,600 cases in 2022, may be preventable. Thus, the rising prevalence of cancer cases in the region is likely to boost the market's growth in the region over the forecast period.

Furthermore, the rise in research funding on chronic pain is also expected to propel the market's growth in the region. For instance, as per NIH 2022, the research funding for chronic pain in the United States for 2021, 2022, and 2023 is estimated at USD 725 million, USD 750 million, and USD 862 million, respectively. In addition, the partnerships and acquisitions among the key market players in the region are also adding to the market's growth. For instance, in January 2022, California-based ICU Medical acquired the Smiths Medical Division, which includes syringe and ambulatory infusion devices, vascular access, and vital care products from Smiths Group Plc. Such activities are likely to expand the portfolio of companies, which are expected to witness significant growth over the forecast period in the North American region.

Patient-controlled Analgesia Pumps Market Competitor Analysis

The PCA pumps market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are developing safe and trouble-free systems with novel technologies, while others are distributing them. Some of the companies that are currently dominating the market are ICU Medical Inc. (Smiths Medical), BD (Becton, Dickinson and Company), Fresenius SE & Co. KGaA, B. Braun SE, and Baxter.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements with Enhanced Safety Features
    • 4.2.2 Rising Prevalence of Chronic Pain Diseases like Cancer and Arthritis
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness Resulting in Patient Medication Errors
    • 4.3.2 Stringent Regulatory Framework and Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 PCA Pumps
    • 5.1.2 Pump Accessories
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Diabetes
    • 5.2.3 Neonatology
    • 5.2.4 Other Applications
  • 5.3 By End Users
    • 5.3.1 Hospital
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Home-care Settings
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United states
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ICU Medical Inc. (Smiths Medical)
    • 6.1.2 Baxter
    • 6.1.3 BD (Becton, Dickinson and Company)
    • 6.1.4 Fresenius SE & Co. KGaA
    • 6.1.5 Micrel Medical Devices
    • 6.1.6 Avante Health Solutions
    • 6.1.7 B. Braun SE
    • 6.1.8 Ace Medical
    • 6.1.9 Terumo Corporation
    • 6.1.10 Abbott
    • 6.1.11 Pfizer Inc. (Hospira)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS